Alentis Therapeutics AG

Privately held: no public share price · Switzerland

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
Claudin-1 (CLDN1)Antibody–drug conjugate
Non-Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell CarcinomaEsophageal Cancer
Esophageal Squamous Cell Carcinoma
Phase 1/2
Claudin-1 (CLDN1)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
ALE.P02Phase 1/2Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma …
Est. primary completion 2028-02-15 · NCT06747585 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
ALE.P03Phase 1/2Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma …
Est. primary completion 2029-04-05 · NCT07169734 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.